TY - JOUR
T1 - Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-Linked hypophosphataemia
T2 - rationale and description
AU - Brandi, Maria Luisa
AU - Ariceta, Gema
AU - Beck-Nielsen, Signe Sparre
AU - Boot, Annemieke M.
AU - Briot, Karine
AU - de Lucas Collantes, Carmen
AU - Emma, Francesco
AU - Giannini, Sandro
AU - Haffner, Dieter
AU - Keen, Richard
AU - Levtchenko, Elena
AU - Makitie, Outi
AU - Nilsson, Ola
AU - Schnabel, Dirk
AU - Tripto-Shkolnik, Liana
AU - Zillikens, M. Carola
AU - Liu, Jonathan
AU - Tudor, Alina
AU - Mughal, M. Zulf
N1 - Funding:The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: Kyowa Kirin International plc is the sponsor of the International XLH Registry and the PASS, and facilitated the development of this document, although its creation was led entirely and independently by the authors. Kyowa Kirin did not provide any direct financial support.
PY - 2022/9/5
Y1 - 2022/9/5
N2 - Background: X-linked hypophosphataemia (XLH) is a rare, inherited, phosphate-wasting disorder that elevates fibroblast growth factor 23 (FGF23), causing renal phosphate-wasting and impaired active vitamin D (1,25(OH)(2)D) synthesis. Disease characteristics include rickets, osteomalacia, odontomalacia, and short stature. Historically, treatment has been oral phosphate and 1,25(OH)(2)D supplements. However, these treatments do not correct the primary pathogenic mechanism or treat all symptoms and can be associated with adverse effects. Burosumab is a recombinant human immunoglobulin G1 monoclonal antibody against FGF23, approved for treating XLH in several geographical regions, including Europe and Israel. Burosumab restores normal serum phosphate levels, minimising the clinical consequences of XLH. Safety data on long-term treatment with burosumab are lacking owing to the rarity of XLH. This post-authorisation safety study (PASS) aims to evaluate the safety outcomes in patients aged >1 year.Methods: The PASS is a 10-year retrospective and prospective cohort study utilising data from the International XLH Registry (NCT03193476), which includes standard diagnostic and monitoring practice data at participating centres. The PASS aims to evaluate frequency and severity of safety outcomes, frequency and outcomes of pregnancies in female patients, and safety outcomes in patients with mild to moderate kidney disease at baseline, in children, adolescents and adults treated with burosumab for XLH. It is expected that there will be at least 400 patients who will be administered burosumab.Results: Data collection started on 24 April 2019. The expected date of the final study report is 31 December 2028, with two interim reports.Conclusion: This PASS will provide data on the long-term safety of burosumab treatment for XLH patients and describe safety outcomes for patients receiving burosumab contrasted with those patients receiving other XLH treatments, to help inform the future management of XLH patients. The PASS will be the largest real-world safety study of burosumab.
AB - Background: X-linked hypophosphataemia (XLH) is a rare, inherited, phosphate-wasting disorder that elevates fibroblast growth factor 23 (FGF23), causing renal phosphate-wasting and impaired active vitamin D (1,25(OH)(2)D) synthesis. Disease characteristics include rickets, osteomalacia, odontomalacia, and short stature. Historically, treatment has been oral phosphate and 1,25(OH)(2)D supplements. However, these treatments do not correct the primary pathogenic mechanism or treat all symptoms and can be associated with adverse effects. Burosumab is a recombinant human immunoglobulin G1 monoclonal antibody against FGF23, approved for treating XLH in several geographical regions, including Europe and Israel. Burosumab restores normal serum phosphate levels, minimising the clinical consequences of XLH. Safety data on long-term treatment with burosumab are lacking owing to the rarity of XLH. This post-authorisation safety study (PASS) aims to evaluate the safety outcomes in patients aged >1 year.Methods: The PASS is a 10-year retrospective and prospective cohort study utilising data from the International XLH Registry (NCT03193476), which includes standard diagnostic and monitoring practice data at participating centres. The PASS aims to evaluate frequency and severity of safety outcomes, frequency and outcomes of pregnancies in female patients, and safety outcomes in patients with mild to moderate kidney disease at baseline, in children, adolescents and adults treated with burosumab for XLH. It is expected that there will be at least 400 patients who will be administered burosumab.Results: Data collection started on 24 April 2019. The expected date of the final study report is 31 December 2028, with two interim reports.Conclusion: This PASS will provide data on the long-term safety of burosumab treatment for XLH patients and describe safety outcomes for patients receiving burosumab contrasted with those patients receiving other XLH treatments, to help inform the future management of XLH patients. The PASS will be the largest real-world safety study of burosumab.
U2 - 10.1177/20406223221117471
DO - 10.1177/20406223221117471
M3 - Article
VL - 13
JO - Therapeutic Advances in Chronic Disease
JF - Therapeutic Advances in Chronic Disease
SN - 2040-6223
ER -
